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Abstract
Background: Increased mammographic density is one of the strongest independent risk factors for breast cancer.
It is believed that one third of breast cancers are derived from breasts with more than 50% density.
Mammographic density is affected by age, BMI, parity, and genetic predisposition. It is also greatly influenced by
hormonal and growth factor changes in a woman’s life cycle, spanning from puberty through adult to menopause.
Genetic variations in genes coding for hormones and growth factors involved in development of the breast are
therefore of great interest. The associations between genetic polymorphisms in genes from the IGF pathway on
mammographic density and circulating levels of IGF1, its binding protein IGFBP3, and their ratio in postmenopausal
women are reported here.
Methods: Samples from 964 postmenopausal Norwegian women aged 55-71 years were collected as a part of the
Tromsø Mammography and Breast Cancer Study. All samples were genotyped for 25 SNPs in IGF1, IGF2, IGF1R,
IGF2R, IGFALS and IGFBP3 using Taqman (ABI). The main statistical analyses were conducted with the PROC
HAPLOTYPE procedure within SAS/GENETICS™ (SAS 9.1.3).
Results: The haplotype analysis revealed six haploblocks within the studied genes. Of those, four had significant
associations with circulating levels of IGF1 or IGFBP3 and/or mammographic density. One haplotype variant in the
IGF1 gene was found to be associated with mammographic density. Within the IGF2 gene one haplotype variant
was associated with levels of both IGF1 and IGFBP3. Two haplotype variants in the IGF2R were associated with the
level of IGF1. Both variants of the IGFBP3 haplotype were associated with the IGFBP3 level and indicate regulation
in cis.
Conclusion: Polymorphisms within the IGF1 gene and related genes were associated with plasma levels of IGF1,
IGFBP3 and mammographic density in this study of postmenopausal women.
Background
Increased mammographic density is one of the strongest
independent risk factors for breast cancer [1-8]. The
risk of developing breast cancer is four to six times
higher in women with dense breast tissue compared to
women with less dense tissue[2]. It has been estimated
that breasts with more than 50% mammographic density
give rise to one third of breast cancer cases[2]. Mammo-
graphic density is thus a stronger cancer risk factor than
the most traditional risk factors such as nulliparity[1],
age at first birth, age at menarche, age at menopause,
use of postmenopausal hormone therapy (HT) and alco-
hol consumption. Mammographic density is influenced
by age[2], body mass index (BMI)[2], parity[2], meno-
pause status[2], HT[1,9], IGF1[10,11] and genetics[2].
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mones and growth factors has been linked to both
increased mammographic density and breast cancer risk.
It has been estimated from twin studies that as much
as 65% of the variation in mammographic density may
be due to hereditary factors[12,13]. The genetic factors
that influence mammographic density might be the
same as the ones involved in the development of breast
cancer[14,15]. The identification of the genes coding for
these factors may therefore provide a better understand-
ing of the genetics and the biology of the breast. Of par-
ticular interest are the insulin-like growth factor 1 and 2
(IGF1/2), which both have the ability to stimulate cell
proliferation and inhibit cell death in many tissue types
[16]. IGF1 is a mitogen predicted to be involved in the
development of several human cancers, including breast
cancer. In addition some studies have shown an associa-
tion between circulating levels of IGF1 and increased
levels of mammographic density [17-21]. In the blood-
stream IGF1 binds to several IGF binding proteins
(IGFBPs) which prolong its half-life and contribute to
its delivery to target tissues[22]. IGFBP3, the principal
carrier of IGF1 and IGF2[23], is mainly regulated by
growth hormone (GH). IGFBP3 itself has the ability to
promote apoptosis[24], thus it is sometimes referred to
as an anticancer protein. The levels of IGF1 and
IGFBP3 combined may be associated with breast cancer
by stimulating proliferation of breast epithelial cells[22].
IGF1 bound to IGFBP3, may bind an acid-labile subunit
(ALS) to form ternary complexes[25]. ALS is synthesized
in the liver upon regulation of growth factors such as
GH. By forming a ternary complex, ALS prolongs the
half-lives of circulating IGFs from 10 minutes (free
form), and 30-39 minutes (binary complex) to more
than 12 hours. As a result, the reservoir of serum IGF1
levels in human adults can reach ~1000 fold that of
insulin[26]. IGF1 and IGF2 both bind to the IGF1 recep-
tor (IGF1R) to exert their growth promoting effects[27].
IGF2 may also bind to the IGF2 receptor (IGF2R) upon
which it is internalized and degraded. Together, envir-
onmental and genetic factors determine the circulating
levels of IGFs and their binding proteins[28]. Previous
studies on polymorphisms/haplotypes in IGFI, IGFBP3
and IGFALS and their association to breast cancer sus-
ceptibility [25,29-31] and circulating levels of both IGFI
[32] and IGFBP3[31] have been reported making them
interesting targets in mammographic density studies.
Tamimi et al. found positive correlation between com-
mon genetic variants in IGF1 and mammographic den-
sity[11]. Since variation in specific genes affects the
levels of IGF1 and IGFBP3 and may influence mammo-
graphic density as well as breast cancer susceptibility,
we set out to analyze 24 SNPs in IGF1, IGF1R, IGF2,
IGF2R, IGFBP3 and IGFALS and their association with
mammographic density and plasma levels of IGF1 and
IGFBP3 among 964 postmenopausal women.
Methods
Study Population
The Tromsø Mammography and Breast Cancer Study
[21,33-37] was conducted among postmenopausal
women, ages 55 to 71 years, residing in the municipality
of Tromsø, Norway, and attending the population-based
Norwegian Breast Cancer Screening Program at the
University Hospital of North Norway. The women were
recruited in the spring of 2001 and 2002. After the
women had undergone their mammographic screening,
they were interviewed by a trained research nurse about
reproductive and menstrual details, previous history of
cancer, smoking status, and use of postmenopausal hor-
mone therapy and other medications. The participants
had their height measured to the nearest centimeter and
their weight measured to the nearest half kilogram. The
women had blood samples drawn and were given a
q u e s t i o n n a i r et ob ec o m p l e t ed at home. The question-
naire elicited information on demographics, additional
menstrual and reproductive factors, as well as lifestyle
and dietary factors. All women signed an informed con-
sent. The National Data Inspection Board and the
Regional Committee for Medical Research Ethics
approved the study. Altogether, 1,041 women were
included in the study. This accounted for 70.1% of the
women attending the Norwegian Breast Cancer Screen-
ing Program during the recruitment period[37].
We excluded 22 women because of a previously (n =
16) or newly (n = 6) diagnosed breast cancer and one
woman because of ongoing chemotherapy treatment.
Women who were 56 years or older or who reported no
menstruation during the last 12 months, or whose
serum follicle-stimulating hormone level was above 20
IU/L, were classified as postmenopausal. By these cri-
teria, three women were equivocal for menopausal sta-
tus and excluded. We further excluded 11 women
whose mammograms were unreadable for technical rea-
sons. Seventeen women with missing blood samples and
23 women due to missing SNP analysis values were also
excluded, leaving 964 women for analysis. More details
are described elsewhere. http://uit.no/density
Mammographic classifications
Left craniocaudal mammograms were digitized using a
Cobrascan CX-812 scanner (Radiographic Digital Ima-
ging, Torrance, CA) at a resolution of 150 pixels/in. Per-
cent and absolute mammographic densities were
determined using the Madena computer-based threshold
method, developed at the University of Southern Cali-
fornia[38]. Briefly, the method was as follows: The digi-
tized mammographic image was viewed on a computer
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of the breast using a computerized tool, and the soft-
ware then counted the number of pixels within the out-
line. Mammographic density was then assessed (by GU)
by first identifying a region of interest that incorporated
all dense areas except those representing the pectoralis
muscle and other scanning artifacts, and then applying a
yellow tint to all pixels within the region of interest
shaded at or above a threshold intensity of gray. The
software then counted the tinted pixels, which represent
t h ea r e ao fa b s o l u t ed e n s i t y(ABDEN). Percent density
(PDEN) equals the amount of absolute density divided
by the total breast area.
The reader of the mammograms did not have any
information of the characteristics of the study partici-
pants. More details are given elsewhere[33].
Peptide Assays
Nonfasting venous blood samples were obtained from
the study participants at the day of mammographic
screening. After centrifugation, plasma samples were
stored at -70°C.
IGF1 and IGFBP3 levels were measured in ng/ml with
the use of ELISA from Diagnostic Systems Laboratories,
Inc. (Webster, TX). The IGF1 assays included an acid-
ethanol precipitation to extract IGF1 from its binding
proteins. Measurements were performed on previously
never-thawed plasma samples.
All IGF1 and IGFBP3 assays were conducted at the
laboratory for hormone analyses (Nutrition and Cancer
Group, IARC, Lyon, France). The mean intrabatch coef-
ficients of variation were 5.1% for IGF1 and 6.1% for
IGFBP3. The interbatch coefficients of variation were
10.6% for IGF1 and 9% for IGFBP3.
The IGF1/IGFBP3 molar ratio was calculated as a pos-
sible indicator of IGF1 bioavailability. More details are
described elsewhere[21].
DNA extraction
Peripheral blood from healthy women was collected in
EDTA-tubes. The DNA was isolated by phenol/chloro-
form extraction followed by ethanol precipitation using
the Applied Biosystems Model 340A Nucleic Acid
Extractor and stored in TE-buffer at 2-8°C. The sample
concentrations were measured by UV/Vis spectrophot-
ometer (Nanodrop ND-1000).
Genotyping methods
5 ng of lyophilized sample DNA was used to perform a
5u lT a q m a n( 5 ’ nuclease assay) reaction. Reactions
were set up using 2.5 ul of the 2× Universal Master Mix
(Applied Biosystems, Foster City, CA) and assay-specific
concentrations of primers and probes. All reactions
were set up in a 384 (96*4) well plate and heat-sealed
using an ABgene ALPS 300 heat sealer and clear heat
sealing film (ABgene, Rochester, NY). Reaction plates
were thermocycled, and endpoint reads were conducted
on the ABI 7900HT sequence detection system. Cluster
Analysis was conducted on the scatter plot of Allele
1 Rn versus Allele 2 Rn. Genotypic segregation was
displayed in the allelic plot, containing four distinct
clusters, which represent the NTCs (no template
controls) and three possible genotypes clusters along the
horizontal, vertical and diagonal axes, which represent
the Allele 1, Allele 2 and Allele 1/Allele 2 respectively.
The data were exported in text format for further analy-
sis. The sequences of the respective probes are given at
http://snp500cancer.nci.nih.gov upon search for each
SNP (rs number).
Statistical analysis
Simple descriptive statistics and other analyses were per-
formed on the final study population with the use of
SAS® 9.1.3 software. For each SNP within the haplotype
regions evaluated, we calculated the allele and genotype
frequencies using programming algorithms written in
Base SAS®.
The haplotype analyses were performed in SAS/
GENETICS using the PROC HAPLOTYPE procedure.
This procedure utilizes the Expectation Maximization
(EM) algorithm to predict the maximum likelihood esti-
mates of the haplotype frequencies assuming Hardy-
Weinberg equilibrium. The standard errors and the con-
fidence intervals are estimated, by default, under a bino-
mial assumption for each haplotype frequency estimate.
In addition, the linkage disequilibrium (LD) option in
PROC HAPLOTYPE was specified which generated a
likelihood ratio test for linkage disequilibrium testing a
null hypothesis of no association between the SNPs
within a given haplotype region. The null hypothesis
was rejected for all haplotype regions evaluated in this
paper; the haplotype frequency estimates from the alter-
native hypothesis are reported here. The haplotype fre-
quency threshold was set to 0.05, and haplotypes with a
lower frequency were not included in the subsequent
haplotype-trend regression analysis done in SAS®.
We applied the programming algorithms for haplo-
type-trend regression as developed by SAS/GENETICS;
these methods also utilize the SAS/STAT procedure
PROC REG for the regression models[39,40]. Haplo-
type-trend regression models [41] were used to assess
whether haplotypes were associated with absolute mam-
mographic density and percent mammographic density
in square centimeters, in addition to the levels of IGF1,
IGFBP3 measured in ng/ml and their molar ratio IGF1/
IGFBP3. Box-Cox transformations were applied to abso-
lute mammographic density and percent density to
more closely approximate a normal distribution in this
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of the Box-Cox transformation were obtained by the
Dynamic programming called the Symplex method[43]
and the code was written in R. All analyses were
adjusted for age and BMI. The haplotypes within a gene
were included individually in a model for comparison to
the other haplotypes within the same gene [11].
For each haplotype region a model with haplotypes
with frequencies >= 0.05 and the covariates age and
BMI was compared to a model with age and BMI
alone; the procedure computed the F statistic and
the two-tailed significance probability for these models.
In addition, all of the above-specified models were
stratified by current HT users versus never and past
HT users.
We also conducted additional analyses stratified by
age and BMI and analyzed with general linear models
using Box-Cox transformed values of mammographic
density as the outcome.
We conducted further analyses of the association
between individual SNPs in the haplotype regions and
each of the outcome measurements. We assessed least
square mean mammographic density by genotype
adjusting for age and BMI using generalized linear mod-
els (PROC GLM). We estimated trend statistics by run-
ning separate models including genotype as an ordinal
variable. For all the above-mentioned analyses we
defined the results as statistically significant if the
p-values were below 0.05.
Results
Characteristics of the Tromsø Mammographic and Breast
Cancer Study
Shown in Table 1 are the selected characteristics of the
participants. The median percent mammographic den-
sity was 9.6% (0.0-69.2%) with a mean of 12.7%
(± 12.2%). The median absolute mammographic density
was 14.8 cm
2 (0.0-155.2 cm
2), with mean of 19.3 cm
2
(± 20.3 cm
2).
Haplotype analysis
The allele and genotype frequencies for all studied SNPs
i nt h eg e n e sI G F 1 ,I G F 1 R ,I G F B P 3 ,I G F 2 ,I G F 2 Ra n d
IGFALS are provided in Table 2.
The estimated common haplotypes (frequency higher
than 5%) for the 6 genes and their association to the
parameters studied are shown in Table 3. Haplotypes in
four of the six studied genes were found significantly
associated with the plasma levels and/or mammographic
d e n s i t y( T a b l e3 ) .O n eh a p l o t y p ev a r i a n tT Gi nIGF1
was significantly associated with an increase in absolute
mammographic density (p = 0.0334). However, upon
stratification by current and past/never use of HT (See
Additional files 1 and 2) this association was no longer
significant (p = 0.1439 and p = 0.1271, respectively). In
IGF2 the rare common haplotype variant CA was asso-
ciated with increased levels of both IGF1 (p = 0.0014)
and IGFBP3 (p = 0.0181), with significant global associa-
tion for these parameters p = 0.0138, p = 0.0408, respec-
tively. After stratification by HT, the association
between this haplotype and IGF1 levels was still statisti-
cally significant (p = 0.0011), and the association with
IGFBP3 levels was borderline statistically significant (p =
0.0730), for women currently taking HT. For women
who were past or never users of HT the association was
no longer significant (p = 0.1261 and 0.2194 respec-
tively). Haplotypes 1 and 5 in the IGF2 receptor (IGF2R)
were found associated with decreased levels of circulat-
ing IGF1, p = 0.0397 and 0.0455, respectively. In addi-
tion, the global p-value of 0.0524 indicated an overall
borderline association of all seven listed haplotypes in
IGF2R with the IGF1 level. Stratification by HT status
also revealed a significant association between haplotype
1 and IGF1 levels in never/past HT users (p = 0.0353),
but not in current users (p = 0.7907). On the other
hand, the association between haplotype 5 and IGF1
levels was no longer statistically significant in never/past
HT users (p = 0.2031) but borderline significant in cur-
rent HT users (p = 0.0637).
Table 1 Selected characteristics of the 964 participants.
All
Mean
Age at screening, y 61.4 (± 4.6)
Age at menarche, y 13.3 (± 1.4)
Age at first birth*, y 22.9 (± 3.7)
Number of children* 2.9 (± 1.3)
Education, y 9.8 (± 3.4)
Age at menopause, y 48.6 (± 5.1)
BMI, kg/m
2 27.3 (± 4.8)
Frequency (%)
Ever Oral Contraceptive use 51.1
Parous 92.6
Ever postmenopausal hormone therapy use 43.4
Current postmenopausal hormone therapy use 26.0
Past postmenopausal hormone therapy use 17.3
Never postmenopausal hormone therapy use 56.6
Breast cancer in first degree relative 8.3
Median
Percent mammographic density, % 9.6 (0-69.2)
Absolute mammographic density, cm
2 14.8 (0-155.2)
Non-dense mammographic area, cm
2 147.0 (21.6-448.9)
IGF1 (ng/ml) 28.7 (2.2-104.6)
IGFBP3 (ng/ml) 151.2 (52.17-241.5)
*Among parous women only.
Data collected as part of the Tromsø Mammography and Breast Cancer(TMBC)
study in Tromsø, Norway in 2001-2002, presented as mean (± standard
deviation), frequency (%), and median (range).
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Gene Gene ID SNP ID Allele 1 frequency
Allele 2 frequency
A1/A1 N = (%)
A1/A2 N = (%)
A2/A2 N = (%)
IGF1 1 IGF1-02 rs6220 T = 0.66703
C = 0.33297
C/C = 104 (11.2)
T/C = 410 (44.2)
T/T = 414 (44.6)
2 IGF1-04 rs2162679 G = 0.16772
A = 0.83228
G/G = 22 (2.3)
G/A = 275 (28.9)
A/A = 654 (68.8)
IGF2 1 IGF2-02 rs734351 T = 0.62393
C = 0.37607
C/C = 129 (13.8)
T/C = 443 (47.5)
T/T = 360 (38.6)
2 IGF2-03 rs3213216 G = 0.61645
A = 0.38355
A/A = 131 (14.0)
G/A = 456 (48.7)
G/G = 349 (37.3)
IGF1R 1 IGF1R-05 rs2137680 G = 0.70768
A = 0.29232
A/A = 92 (9.7)
G/A = 372 (39.1)
G/G = 487 (51.2)
2 IGF1R-18 rs2175795 G = 0.70952
A = 0.29048
A/A = 90 (9.5)
G/A = 369 (39.0)
G/G = 486 (51.4)
3 IGF1R-06 rs907806 G = 0.09201
A = 0.90799
G/G = 15 (1.6)
G/A = 145 (15.2)
A/A = 791 (83.2)
4 IGF1R-04 rs3743258 G = 0.72569
A = 0.27431
A/A = 71 (7.5)
G/A = 377 (39.9)
G/G = 498 (52.6)
5 IGF1R-26 rs3743259 G = 0.30765
A = 0.69235
G/G = 86 (9.1)
G/A = 407 (43.3)
A/A = 448 (47.6)
6 IGF1R-03 rs2272037 C = 0.57354
T = 0.42646
T/T = 171 (18.1)
C/T = 464 (49.1)
C/C = 310 (32.8)
7 IGF1R-01 rs2229765 G = 0.56019
A = 0.43981
A/A = 184 (19.4)
G/A = 465 (49.1)
G/G = 298 (31.5)
8 IGF1R-07 rs2016347 T = 0.52784
G = 0.47216
G/G = 202 (21.2)
T/G = 495 (52.0)
T/T = 255 (26.8)
IGF2R 1 IGF2R-05 rs1570070 A = 0.63097
G = 0.36903
G/G = 132 (14.0)
A/G = 432 (45.8)
A/A = 379 (40.2)
2 IGF2R-01 rs894817 G = 0.68873
A = 0.31127
A/A = 97 (10.6)
G/A = 375 (41.0)
G/G = 442 (48.4)
3 IGF2R-02 rs998075 G = 0.49840
A = 0.50160
G/G = 235 (25)
G/A = 467 (49.7)
A/A = 238 (25.3)
4 IGF2R-11 rs998074 C = 0.50211
T = 0.49789
T/T = 235 (24.8)
C/T = 474 (50)
C/C = 239 (25.2)
5 IGF2R-04 rs629849 G = 0.86456
A = 0.13544
A/A = 21 (2.2)
G/A = 211 (22.6)
G/G = 702 (75.2)
6 IGF2R-07 rs2282140 C = 0.89504
T = 0.10496
T/T = 6 (0.6)
C/T = 187 (19.7)
C/C = 755 (79.6)
7 IGF2R-03 rs1803989 T = 0.09746
C = 0.90254
T/T = 10 (1.1)
T/C = 164 (17.4)
C/C = 770 (81.6)
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nificantly associated with IGFBP3 plasma levels with a
global p-value of 0.0009. Haplotype variant 1 was asso-
ciated with lower IGFBP3 levels (p = 0.0009) whilst hap-
lotype 2 was associated with increased IGFBP3 levels (p
= 0.0008). After stratification by HT, these associations
were still significant in the group that were never/past
HT users (p = 0.004 and 0.003 for haplotypes 1 and 2
respectively) but not among current HT users (p =
0.3833 and 0.4220).
None of the common haplotypes within the IGF1
receptor (IGF1R) haplotype or IGFALS haplotype were
found significantly associated with any of the parameters
studied. There was a borderline association between
IGFALS haplotype 1 and 3 and IGFBP3 levels (p =
0.0582 and 0.0769 respectively). After stratification by
HT, haplotype 1 was significantly associated with the
IGFBP3 level (p = 0.0309), while haplotype 3 was still
borderline significant (p = 0.0639) in the never/past HT
group.
Stratified analysis by age and BMI
We examined if the significant association found
between IGF1 haplotype 4 and absolute mammographic
density was specific to groups of age or BMI, and strati-
fied the analysis by tertiles of age and tertiles of BMI
(see Additional file 3). Women within the age groups
> = 59 to < 64, and > = 64 years (Tertile 2 and 3) carry-
ing the haplotype 4 variant had a trend towards higher
levels of mammographic density (p = 0.0976, p =
0.0879). Stratification by BMI, revealed a trend towards
higher levels of mammographic density (p = 0.0989) for
the women in BMI tertile 2.
Single SNP analysis
In the six abovementioned genes we had 24 SNPs that
were analyzed for association to the levels of IGF1,
IGFBP3 and mammographic density (see Additional
file 4). Eight of the 24 SNPs were found to be signifi-
cantly associated with one or more of the parameters
studied. In IGF1R, rs907806 was found to be signifi-
cantly associated with the levels of IGFBP3 (p-trend =
0.0111). SNP rs3743259 was found to be significantly
associated with mammographic density measured as
both percent (p-trend = 0.0328) and absolute (p-trend =
0.0389) mammographic density. SNP rs2229765 and
rs2016347 were significantly associated with mammo-
graphic density measured as both percent and absolute
mammographic density, p-trend = 0.0265 and 0.0100,
and, p-trend = 0.0434 and 0.0160 respectively. In IGF2R,
rs998075 and rs998074 were found significantly asso-
ciated with IGF1 (p-trend = 0.0072, p-trend = 0.0083)
and IGFBP3 levels (p-trend = 0.0359, p-trend = 0.0320).
In IGFALS, rs9282731 was found significantly asso-
ciated with the levels of IGFBP3 (p-trend = 0.0205). In
IGFBP3, rs2471551 was found significantly associated
with the levels of IGFBP3 (p-trend = 0.0009), denoting
an association in cis.
Discussion
This population-based cross-sectional study shows an
association between a common genetic haplotype in
IGF1 and absolute mammographic density in postmeno-
pausal women after adjustment for age and BMI.
Although not statistically significant, stratification by age
and BMI revealed that the upper age tertiles and middle
BMI tertile increased the mammographic density level.
One haplotype in IGF2 was associated with the levels of
both IGF1 and IGFBP3, while two haplotypes in the
IGF2R gene were associated with the levels of IGF1.
Within the IGFBP3 gene, two haplotypes were found
associated with the IGFBP3 level indicating a regulation
in cis.
The strength of our study is the large sample size and
the fact that the samples were collected as part of a
population-based screening project with high attendance
Table 2: Allele and genotype frequencies of the 964 participants. (Continued)
IGFALS 1 IGFALS-05 rs9282731 T = 0.00105
C = 0.99895
T/T = 0 (0)
T/C = 2 (0.2)
C/C = 946 (99.8)
2 IGFALS-01 rs17559 T = 0.09057
C = 0.90943
T/T = 13 (1.4)
T/C = 145 (15.4)
C/C = 786 (83.3)
3 IGFALS-02 rs3751893 T = 0.21186
C = 0.78814
T/T = 41 (4.3)
T/C = 318 (33.7)
C/C = 585 (62.0)
IGFBP3 1 IGFBP3-05 rs9282734 C = 0.00317
A = 0.99683
C/C = 0 (0)
C/A = 6 (0.6)
A/A = 941 (99.4)
2 IGFBP3-04 rs2471551 G = 0.17766
C = 0.82234
G/G = 27 (2.9)
G/C = 280 (29.8)
C/C = 633 (67.3)
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IGF1 level IGFBP3 level IGFratio PDEN
a ABDEN
b
IGF1
Haplotype Frequency p-value p-value p-value p-value p-value
1. CG 0,1185 0.5553 0.9493 0.6462 0.2337 0.2693
2. CA 0,21486 0.1424 0.5075 0.4549 0.5147 0.6701
3. TA 0,61718 0.7733 0.7103 0.9016 0.4486 0.8462
4. TG 0,04947 0.1683 0.7237 0.2713 0.1737 0.0334
Global association 0.3342 0.924 0.6641 0.3069 0.1167
IGF2
Haplotype Frequency p-value p-value p-value p-value p-value
1. TG 0,34537 0.2769 0.9845 0.1648 0.2297 0.4051
2. CG 0,27102 0.6093 0.1440 0.3058 0.5776 0.7190
3. TA 0,27821 0.7660 0.9920 0.5860 0.5254 0.6165
4. CA 0,10541 0.0014 0.0181 0.0974 0.8518 0.9403
Global association 0.0138 0.0408 0.2712 0.6353 0.8313
IGF1R
Haplotype Frequency p-value p-value p-value p-value p-value
1. GGAGATGT 0,09532 0.8216 0.6761 0.7512 0.8689 0.9008
2. GGAGATAG 0,07847 0.1245 0.0885 0.5697 0.1153 0.1678
3. GGAGACGT 0,12829 0.8324 0.9646 0.9343 0.4403 0.6585
4. GGAAGCAG 0,05028 0.4479 0.6971 0.4485 0.7200 0.8879
5. GGAGACAG 0,10502 0.8550 0.9531 0.8820 0.1567 0.2125
Global association 0.5384 0.5162 0.8893 0.3016 0.4638
IGF2R
Haplotype Frequency p-value p-value p-value p-value p-value
1. GAATACC 0,06242 0.0397 0.1228 0.2853 0.2140 0.0784
2. AGGCGCC 0,27961 0.2376 0.3324 0.5912 0.7018 0.6786
3. GAGCGTC 0,06251 0.7378 0.8651 0.9925 0.9465 0.7463
4. GAATGCC 0,11233 0.4057 0.4787 0.9129 0.7414 0.5293
5. AGATGCC 0,2451 0.0455 0.0631 0.4429 0.7105 0.8569
6. AGATACC 0,07038 0.4484 0.3361 0.8486 0.9180 0.8191
7. GAGCGCT 0,06327 0.5430 0.4985 0.6552 0.0575 0.0622
Global association 0.0524 0.1619 0.8720 0.5036 0.2659
IGFals
Haplotype Frequency p-value p-value p-value p-value p-value
1. CTC 0,08951 0.8055 0.0582 0.2993 0.4069 0.5648
2. CCC 0,69765 0.2290 0.6156 0.3095 0.8880 0.9099
3. CCT 0,21171 0.1412 0.0769 0.6082 0.6291 0.7605
Global association 0.3387 0.0523 0.4678 0.6624 0.8261
IGFBP3
Haplotype Frequency p-value p-value p-value p-value p-value
1. AG 0,17767 0.1630 0.0009 0.1595 0.5689 0.2204
2. AC 0,81917 0.1635 0.0008 0.1531 0.5551 0.2302
Global association 0.1630 0.0009 0.1595 0.5689 0.2204
All associations are adjusted by age and BMI. Significant p-values (< 0,05) are marked in bold italics.
aPDEN: Percent Density.
bABDEN: Absolute Density, measured in cm
2.
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to the characteristics of the women performed the read-
ing and measurements of both the mammographic den-
sity and hormone levels. Also, we had information on
age, BMI and HT use and were able to both adjust and
stratify for these variables when necessary.
The limitation of our study is that the associations
made with the polymorphisms within IGF2R were diffi-
cult to interpret due to the lack of measurements of its
ligand IGF2. The women in the study were all postme-
nopausal, and some were taking HT, which could influ-
ence the circulating levels of IGF1 and IGFBP3.
Furthermore, HT is demonstrated to have an impact on
mammographic measurements, increasing the density.
However, as HT cannot have influenced genotype, it is
not technically a confounder, and as in most other ana-
lyses of mammographic density, we adjusted for age and
BMI. We did however, stratify for HT, predominantly
because of the possibility that HT use could be an effect
m o d i f i e r ,i . e .h a v em o d i f i e dt h ee f f e c to fg e n o t y p eo n
mammographic density.
Mammographic density is reduced by successive preg-
nancies and menopause, as well as with advancing age.
Furthermore, mammographic density may reflect the
cumulative exposure to hormones and growth factors
that stimulate cell division and growth in the breast.
Pike and colleagues proposed a model, stating that the
effects of hormone exposure throughout life and the
accumulation of genetic damage may cause an increased
probability of breast cancer later in life [44]. The age-
specific absolute risk of breast cancer caused by mam-
mographic density is not yet determined, and it is
unknown whether interventions that reduce cumulative
exposure to density will reduce risk of breast cancer [2].
Because of the role of the IGF pathway in breast devel-
opment and cellular proliferation, genetic variation
within this pathway is of interest. Similar to mammo-
graphic density, IGF1 levels are related to age [22], BMI
[45], and menopause status[21] and young women tend
to have higher IGF1 levels than women in their postme-
nopausal years[22].
A positive association of IGF1 and IGFBP3 levels in
relation to mammographic density in premenopausal
women was found in most[17-20,32]but not all [46-48]
previous studies. In postmenopausal women however
the results are less consistent [18-21,47]. Data already
published from this study were positive[21], suggesting
an association between IGF1 and mammographic den-
sity. Our finding of a common haplotype in IGF1 asso-
ciated with mammographic density is in agreement with
previously published findings of an association with
IGF1 levels and density. Associations of genetic variants
in IGF1 and mammographic density in postmenopausal
women can potentially better reflect the lifetime
exposure of IGF1[11] compared to the IGF1 level mea-
sured at a certain time point, at a late stage, in a
woman’s life.
Other studies [18-20,46,47] such as the one of Dos
Santos Silva et al. found no association between postme-
nopausal mammographic density and levels of IGF1,
IGF2 or IGFBP3, nor the ratio of IGF1/IGFBP3,
although, there was an association between the mammo-
graphic lucent area and IGFBP3 serum levels[47]. In
summary, many studies have looked at variations in the
IGF genes and their relationship with IGF plasma levels
and mammographic density, but the results remain
inconclusive, emphasizing the need for more studies.
The incidence of breast cancer has been associated
with levels of IGF1 and IGFBP3 in premenopausal
women in most [22,49-53], but not all studies [54,55].
Hankinson et al. performed a nested case-control study
and found that IGF1 levels were higher among preme-
nopausal women who developed breast cancer before
age 50 than among age matched women who remained
cancer free. For the postmenopausal women in the
study no such association was established[22]. In post-
menopausal women the findings are less clear and posi-
tive association of either IGF1, IGFBP3 or both with
breast cancer [49,50,56] has been reported while other
studies are negative[22,54,57]. The use of HT by post-
menopausal women is known to lower both IGF1 and
IGFBP3 levels significantly; thus the IGF1-associated
increase in mammographic density seen in the non-HT
users, may be difficult to observe in the HT users[21].
Nevertheless, one study reported an increased risk of
breast cancer with increasing IGF1 levels also for post-
menopausal HT-users (>55 years)[54]. Despite lowering
the IGF1 levels, HT increases the mammographic den-
sity for most women and the age related decrease in
mammographic density around the age of 55-64 does
not commence in these women [58]. These findings
support an emerging model of crosstalk between IGF1
and estrogens, suggesting that estrogens act through
their receptor (ER) and affect the IGF1 expression[59].
IGF1 haplotypes
Variation in mammographic density due to polymorph-
isms in the IGF1 gene has been reported in both pre-
and postmenopausal women, but the association
between genetic variants in IGF1 and mammographic
density in breast tissue in postmenopausal women has
been inconclusive [11,17,46].
Among the common haplotypes analyzed in IGF1 the
least frequent haplotype was statistically significantly
associated with an increase in ABDEN levels. This hap-
lotype consists of the major allele of rs6220 and the
minor allele of rs2162679. Other studies have reported
an association between the minor allele of rs6220 and
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but to our knowledge, no other study has looked at this
SNP in relation to postmenopausal mammographic den-
sity. Separately, the SNPs comprising this haplotype
have been reported to be associated with IGF1 levels
and breast cancer risk. The polymorphism rs6220 has
also been correlated with elevated IGF1 levels whereas
homozygosity G/G of rs2162679, has been associated
with reduced breast cancer risk as well as reduced levels
of IGFBP3[25]. This is in agreement with our observa-
tion of increased mammographic density for haplotype
4, given that low levels of IGFBP3 and high levels of
IGF1 have been reported to increase mammographic
density[19].
It is surprising to find the IGF1 haplotype associated
with increased mammographic density most strongly in
women with higher BMI at an older age. However, since
postmenopausal production of estrogens takes place
predominantly in the adipose tissue, an increase in BMI
would hypothetically result in increased estrogen levels.
In turn estrogens may increase cellular IGF1 through
crosstalk, and IGF1 may up-regulate the receptor
response to estrogens[61]. This haplotype has a fre-
quency of 0.04947 in the population studied which
equal to 45 women and could be said to have little
power. However, similar results have been reported by
Muti et al. who reported that heavier postmenopausal
women (BMI>26) had IGF1 levels associated with breast
cancer risk [61]. Analysis of the SNPs in IGF1 did not
reveal any significant associations with any of the para-
meters studied (IGF1, IGFBP3, IGFratio or mammo-
g r a p h i cd e n s i t y ) ,a n dt h u sw ew e r eu n a b l et ov e r i f yt h e
previous findings regarding these SNPs and association
to IGF1 levels and breast cancer risk. However, this is
an indication that the aforementioned association of the
IGF1 haplotype 4 with mammographic density is depen-
dent on the co-occurrence of these two SNPs.
IGFBP3 haplotypes
Several associations of IGFBP3 polymorphisms and
levels of IGFBP3 have been reported [25,46,47,62,63]
one example is the -202(rs2854744) polymorphism asso-
ciated with increased levels of IGFBP3 [46,47,62]. The
-202 SNP has been associated with levels of IGF1 [60],
IGFBP3 [46,47,60] and premenopausal mammographic
density [46] but not with postmenopausal mammo-
graphic density [46,47]. The present study examined
SNPs in the surrounding area of the -202 polymorphism
which is an area suggested to be in strong LD[25,64].
The two IGFBP3 haplotypes analyzed here were found
to be significantly associated with the levels of IGFBP3
suggesting a putative regulatory effect in cis.T h eC
allele of SNP rs2471551 of the IGFBP3 haplotype has
previously been associated with increased levels of
IGFBP3 in combination with surrounding SNPs[25].
Upon single SNP analysis we found a significant trend
of SNP rs2471551 with the level of IGFBP3 indicating
that having two copies of the frequent allele C increase
the least square mean of IGFBP3 compared to having
two copies of the rare allele G, confirming the finding of
Canzian et al. 2006. In the haplotype analysis we found
that the AC haplotype was associated with higher levels
of IGFBP3 than the AG haplotype and can thus confirm
the result published by Canzian et al.t h a tS N P
rs2471551 is associated with increased IGFBP3 levels
[25]. In addition, these haplotypes signify a trend of
association with low levels (AG) and high levels (AC) of
mammographic density (Table 3). These findings are
consistent with the review of Fletcher et al.i nw h i c h
most reports agree on increased breast cancer risk with
high levels of IGFBP3[65]. This may most strongly apply
to premenopausal women, in whom the IGF levels are
higher than in postmenopausal[22], and where the IGF
axis is postulated to have an increased role because of
involvement of the sex hormones[52]. The emerging
belief that higher levels of IGFBP3 may decrease mam-
mographic density and may decrease the risk of cancer
[22,25,66] through low IGF1/IGFBP3 ratio must be
further substantiated.
IGF2 haplotypes
Even though it is known that the circulating IGF2 con-
centration is much higher than that of IGF1, there is
limited evidence on its mitogenic activity in relation to
breast cancer and disease[47,49,56], thus implications of
IGF2 on breast cancer risk are inconclusive. Studies on
genetic variants of IGF2 in relation to breast disease are
few, and to our knowledge, the present study is the first
to look at IGF2 polymorphisms in relation to levels of
mammographic density, IGF1 and IGFBP3. The finding
of a common haplotype (4, Table 3) significantly asso-
ciated with higher levels of both IGF1 and IGFBP3 may
be explained by a decrease in clearance of IGF1 due to
potentially lower levels of IGF2. IGFBP3 is the principal
carrier of both IGF1 and IGF2a n dt h ep o s s i b i l i t yo fa
regulatory feedback of IGF1 and IGFBP3 through poly-
morphisms in IGF2 cannot be excluded. However, we
did not have measurements of IGF2 and could therefore
not test this. The association with haplotype 4 was no
longer seen in analyses of the single IGF2 SNPs and
thus there is reason to believe that the association is
dependent on the combination of the two SNPs com-
prising this haplotype. After stratifying the analysis by
HT the association was still significant for the women
currently taking HT, implying that HT could be an
effect modifier of this association. The sex hormones
play an important role in the IGF axis and could be the
reason why the association is stronger in these women.
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The IGF1 receptor (IGF1R) sets off a complex cascade
of signals upon binding of its ligands, IGF1 and IGF2
[67]. IGF1R functions as an anti-apoptotic agent by
enhancing cell survival, and has been found expressed in
most breast cancer cell lines[68] and highly over-
expressed in most malignant tissues[69]. In a study on
genetic variation and breast cancer survival, Deming et
al. [64] found SNP rs951715 within the IGF1R gene
associated with breast cancer survival in postmenopausal
women, whereas SNP rs2229765 included in the present
study, was not[64]. SNP rs2229765 results in a silent
mutation, and has thus far not been found associated
with any epidemiological traits. In the haplotype analysis
none of the IGF1R haplotypes were found significantly
associated with any of the studied parameters. The sin-
gle SNP analysis revealed significant association of SNP
rs2229765 with both percent and absolute mammo-
graphic density, increased numbers of the G allele
increased the least squares means of mammographic
density. In addition the SNPs rs3743259 and rs2016347
were also significantly associated with percent and abso-
lute mammographic density, and in both cases increased
number of the most frequent allele increased the least
square mean of mammographic density. Functional stu-
dies are needed to investigate if these SNPs influence
the affinity to IGF1 and IGF2 increasing their growth
promoting effects and possibly mammographic density.
IGF2R haplotypes
IGF1 and IGF2 send their mitogenic and antiapoptotic
signals through a common thyrosine kinase receptor,
the IGF1R. Modulation of the mitogenic pathway occurs
in part via the M6P/IGF2R, which functions in the
internalization and degradation of IGF2[27]. IGF2R is
also important in the activation process of TGFb,w h i c h
amongst other properties has the ability to inhibit cell
growth. Loss of heterozygosity (LOH) of the M6P/
IGF2R has been linked to liver and breast cancers,
whereas somatic mutations of the M6P/IGF2R have
been found in cancers of the prostate, lung, endome-
trium, brain, stomach and colorectum[27]. Chen et al.
found that decreased ribosomal expression of the recep-
tor leads to increased proliferation of MCF7 cells by a
IGF2 related mechanism, mediated through IGF1R [27].
These findings have led to the suggestion that IGF2R is
a tumor suppressor gene. Our results show that two of
the IGF2R haplotypes are significantly associated to
decreased levels of IGF1. For haplotype 1 the association
was still significant after stratification for HT, in women
that are never or past users of HT. Postmenopausal
women that are not under the influence of hormones
potentially have lower IGF1 levels. Analysis performed
o nt h ei n d i v i d u a lS N P ss u p p o r t st h i sf i n d i n g ,w i t ha
significant association of two IGF2R SNPs and the levels
of IGF1, in addition they are also significantly associated
with the levels of IGFBP3. IGF1 which is produced in
the liver is influenced by several factors such as growth
hormone and insulin, and its bioavailability is regulated
by IGF2, IGFBPs and Als (acid-labile protein subunit)
[65]. It is well known that IGF2 can act through IGF1R,
in contrast IGF1 does not act through IGF2R, and to
our knowledge no association between IGF2R and IGF1
levels have been described. IGF2R is able to degrade
IGF2 and thereby regulates the circulating concentration
of IGF2, in turn IGF2 clearance has the ability to regu-
late the level of IGF1. Thus, a possible explanation for
the association of the two haplotypes and the SNP
within IGF2R with IGF1 levels could be a change in
clearance of IGF2 levels leading to decreased production
of IGF1 through a regulative feedback loop. Whether or
not such an interaction is present between IGF2 and
IGF1 levels is impossible to confirm, due to lacking
measurements of circulating IGF2.
IGFALS haplotypes
Despite being an important member in IGF regulation,
few studies have looked at this protein and variations
within it in regards to breast cancer[25,64]. Canzian
et al. [25] studied three SNPs within exon 2 of IGFALS
in regards to breast cancer risk, two of which are
included in the IGFALS haplotype of our study
(rs3751893, rs17559), and found that homozygous
carriers of SNP rs3751893 were associated with reduced
circulating levels of IGF1. Deming et al.c o n d u c t e da
study on IGFALS promoter SNPs in relation to meno-
pausal status but found no association [64].
The IGFALS haplotypes in this study were not signifi-
cantly associated with neither the levels of IGF1,
IGFBP3, their ratio nor mammographic density. Stratifi-
cation by HT of the haplotype analysis revealed a signifi-
cant association of the never/past HT group with the
level of IGFBP3, in addition the SNP analysis revealed
significant association of SNP rs9282731 with the level
of IGFBP3. Increased number of the C allele increases
the IGFBP3 level compared to the rare allele G. One
hypothesis could be that the C allele modifies the
IGFALS and reduces either its affinity or reduces its
level causing increased level of free IGFBP3. Although
the SNP analysis is based on low frequencies, functional
studies could to be done to verify such a hypothesis.
Further investigation into the role of this protein is
needed to establish its involvement in the development
of mammographic density and breast cancer.
Conclusion
In conclusion, haplotypes were defined for each of the
six genes from the IGF pathway studied here. Four
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cantly associated with the metabolic levels of the gene
products and mammographic density. One haplotype
variant in IGF1 was found associated with mammo-
graphic density. In IGF2 one haplotype variant was asso-
ciated with the level of both IGF1 and IGFBP3. Two
haplotype variants and two SNPs in IGF2R were asso-
ciated with the levels of IGF1. Both variants of the
IGFBP3 haplotype and one SNP were associated with
IGFBP3 level, indicating a regulatory function in cis.
Additional file 1: Haplotype analysis stratified by current HT use.
Associations of the common haplotypes with IGF1, IGFBP3 and
mammographic density levels stratified by current HT use.
Additional file 2: Haplotype analysis stratified by never/past HT use.
Associations of the common haplotypes with IGF1, IGFBP3 and
mammographic density levels stratified by never past HT use.
Additional file 3: IGF haplotype association stratified by age and
BMI. Significant association of IGF1 haplotype 4 with ABDEN stratified by
age and BMI tertiles.
Additional file 4: Associations of single SNPs with IGF1, IGFBP3
levels, IGFratio, and mammographic density. PDEN-Percent Density,
ABDEN-Absolute density. LSMEANS-Least squares Means. Measurements
of mammographic density are boxcox transformed.
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